Intermittent β-adrenergic blockade downregulates the gene expression of β-myosin heavy chain in the mouse heart

Eur J Pharmacol. 2020 Sep 5:882:173287. doi: 10.1016/j.ejphar.2020.173287. Epub 2020 Jun 22.

Abstract

Expression of the β-myosin heavy chain (β-MHC), a major component of the cardiac contractile apparatus, is tightly regulated as even modest increases can be detrimental to heart under stress. In healthy hearts, continuous inhibition of β-adrenergic tone upregulates β-MHC expression. However, it is unknown whether the duration of the β-adrenergic inhibition and β-MHC expression are related. Here, we evaluated the effects of intermittent β-blockade on cardiac β-MHC expression. To this end, the β-blocker propranolol, at the dose of 15mg/kg, was administered once a day in mice for 14 days. This dosing schedule caused daily drug-free periods of at least 6 h as evidenced by propranolol plasma concentrations and cardiac β-adrenergic responsiveness. Under these conditions, β-MHC expression decreased by about 75% compared to controls. This effect was abolished in mice lacking β1- but not β2-adrenergic receptors (β-AR) indicating that β-MHC expression is regulated in a β1-AR-dependent manner. In β1-AR knockout mice, the baseline β-MHC expression was fourfold higher than in wild-type mice. Also, we evaluated the impact of intermittent β-blockade on β-MHC expression in mice with systolic dysfunction, in which an increased β-MHC expression occurs. At 3 weeks after myocardial infarction, mice showed systolic dysfunction and upregulation of β-MHC expression. Intermittent β-blockade decreased β-MHC expression while attenuating cardiac dysfunction. In vitro studies showed that propranolol does not affect β-MHC expression on its own but antagonizes catecholamine effects on β-MHC expression. In conclusion, a direct relationship occurs between the duration of the β-adrenergic inhibition and β-MHC expression through the β1-AR.

Keywords: Gene expression; β-adrenergic receptors; β-blockers; β-myosin heavy chain.

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / blood
  • Adrenergic beta-Antagonists / pharmacokinetics
  • Adrenergic beta-Antagonists / pharmacology*
  • Adrenergic beta-Antagonists / therapeutic use
  • Animals
  • Down-Regulation / drug effects
  • Female
  • Isoproterenol / pharmacology
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / genetics
  • Myocardial Infarction / pathology
  • Myocardium / metabolism*
  • Myosin Heavy Chains / genetics*
  • Propranolol / blood
  • Propranolol / pharmacokinetics
  • Propranolol / pharmacology*
  • Propranolol / therapeutic use
  • Receptors, Adrenergic, beta / genetics*
  • Ventricular Myosins / genetics*

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Receptors, Adrenergic, beta
  • Propranolol
  • Ventricular Myosins
  • Myosin Heavy Chains
  • Isoproterenol